Your browser does not support JavaScript capabilities, which maybe required to display this page properly.


PDF FormatRequires Adobe Acrobat Reader

Table 10.6h

Persistency of Discharge Regimen by Follow-up Period, 2003 to 2007

Recipients with Intestine Transplants

  Year of Transplant
2003 2004 2005 2006 2007
Discharge Regimen (w/ or w/o Steroid Use) Tac+Aza At Discharge (N) - - - 1 3
At Discharge (%) - - - 100.0% 100.0%
6 Months PostTx (%) - - - 100.0% 66.7%
1 Year PostTx (%) - - - 100.0% 66.7%
2 Years PostTx (%) - - - 100.0% -
3 Years PostTx (%) - - - - -
Tac+MMF At Discharge (N) 7 11 19 26 33
At Discharge (%) 100.0% 100.0% 100.0% 100.0% 100.0%
6 Months PostTx (%) 71.4% 80.0% 73.7% 42.3% 69.7%
1 Year PostTx (%) 57.1% 70.0% 52.6% 42.3% 45.4%
2 Years PostTx (%) 57.1% 70.0% 52.6% 37.6% -
3 Years PostTx (%) 42.9% 60.0% 47.4% - -
Tac+Siro At Discharge (N) 4 14 18 14 11
At Discharge (%) 100.0% 100.0% 100.0% 100.0% 100.0%
6 Months PostTx (%) 75.0% 71.4% 83.3% 78.6% 27.3%
1 Year PostTx (%) 0.0% 50.0% 50.0% 28.6% 18.2%
2 Years PostTx (%) 0.0% 50.0% 33.3% 28.6% -
3 Years PostTx (%) 0.0% 35.7% 27.8% 28.6% -


Source: OPTN/SRTR Data as of May 4, 2009.

Regimen change is defined as being on different drug combination at follow-up comparing to discharge, or indication of conflicting regimen (CyA vs. Tac; MMF/MPA vs. Aza; Siro vs. Evero) during follow-up period, or graft failure/death. Addition or deletion of steroids is not considered a regimen change.Rates are calculated for the most common discharge regimens.

CyA: Cyclosporine; Tac: Tacrolimus; MMF: Include MMF(Mycophenolate Mofetil) and MPA(Mycophenolate Sodium); Aza: Azathioprine; Siro: Sirolimus.

See Technical Notes for further details.



PDF FormatRequires Adobe Acrobat Reader